AxoGen is a regenerative medicine company focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and reconstruction to help patients suffering from traumatic injuries or undergoing surgeries that impact the function of their peripheral nerves. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Damage to a peripheral nerve can result in the loss of muscle or organ function, the loss of sensory feeling or pain and can significantly impact the patient's quality of life. The company has licensed technologies from University of Floridas McKnight Brain Institute, the University of Texas and other research institutions, as well as developed its own technologies. The firm combines scientific advancements that reveal the mechanism of axon growth and regeneration, and have incorporated them into the company's products to help surgeons repair peripheral nerve damage. The AXOGEN nerve graft enables the repair and regeneration of peripheral nerves. It is an allograft nerve that is minimally processed to preserve the three dimensional structure and growth promoters while clearing the nerve graft from cellular materials and growth inhibitors. The resulting nerve graft provides a pathway for nerve regeneration without requiring immunosuppression. Formerly known as AxoGen Corporation, Axogen reverese merged with LecTec Corporation in 2011 and was subsequently renamed AxoGen, Inc.
